Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.89
+0.11502.41%
Volume:16.34M
Turnover:78.41M
Market Cap:2.12B
PE:-2.71
High:4.92
Open:4.82
Low:4.66
Close:4.77
52wk High:12.36
52wk Low:3.79
Shares:434.15M
Float Shares:415.00M
Volume Ratio:0.89
T/O Rate:3.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8042
EPS(LYR):-1.6909
ROE:-86.34%
ROA:-39.08%
PB:2.31
PE(LYR):-2.89

Loading ...

CEO Christopher Gibson Reports Disposal of Common Shares of Recursion Pharmaceuticals Inc

Reuters
·
Sep 13

Recursion Pharmaceuticals Price Target Maintained With a $8.00/Share by Needham

Dow Jones
·
Sep 11

Strategic Growth and Unique Positioning Drive Buy Rating for Recursion Pharmaceuticals

TIPRANKS
·
Sep 11

Recursion Pharmaceuticals Issues Amendment to July 8, 2025 Report, Registers 2.4 Million Shares for Resale

Reuters
·
Aug 30

CEO Christopher Gibson Reports Disposal of Common Shares of Recursion Pharmaceuticals Inc

Reuters
·
Aug 29

Chief R&D Commercial Officer Najat Khan Reports Disposal of Recursion Pharmaceuticals Common Shares

Reuters
·
Aug 20

Christopher Gibson, CEO, Reports Disposal of Recursion Pharmaceuticals Inc. Common Shares

Reuters
·
Aug 14

Nvidia-Linked Shares Rally. SoundHound AI up 21%; Nebius, CoreWeave up 7%

Tiger Newspress
·
Aug 08

Stock Track | Recursion Pharmaceuticals Plummets 5% as Q2 Losses Widen Despite Revenue Beat

Stock Track
·
Aug 05

Stock Track | Recursion Pharmaceuticals Plummets 5% After Q2 Earnings Miss and Widened Losses

Stock Track
·
Aug 05

Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises

MT Newswires Live
·
Aug 05

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Net Loss $0.41 a Share, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
Aug 05

Stock Track | Recursion Pharmaceuticals Soars 7.93% Pre-Market on Q2 Revenue Beat and Clinical Trial Progress

Stock Track
·
Aug 05

Recursion's Cash Position As Of June 30, 2025 Was $533.8M, Expected To Extend Cash Runway Into The Fourth Quarter Of 2027

Benzinga
·
Aug 05

Recursion Pharmaceuticals Q2 2025 EPS $(0.41) Misses $(0.34) Estimate, Sales $19.223M Beat $16.233M Estimate

Benzinga
·
Aug 05

Recursion Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Reuters
·
Aug 05

Recursion Pharmaceuticals Q2 Operating Revenue USD 19.103 Million VS. Ibes Estimate USD 15.4 Million

THOMSON REUTERS
·
Aug 05

Recursion Pharmaceuticals Q2 EPS USD -0.41

THOMSON REUTERS
·
Aug 05

Nvidia-Linked Shares Rally. APLD up 9%; Nano-X Imaging, Serve Robotics up 5%; Nebius up 4%

Tiger Newspress
·
Aug 04

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

GlobeNewswire
·
Jul 29